Whole Cell Vaccines

  • Mark B. Faries
  • Donald L. Morton


Dendritic Cell Major Histocompatibility Complex Major Histocompatibility Complex Class Major Histocompatibility Complex Molecule Cell Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Coley W. Treatment of inoperable malignant tumors with the toxins of erysipelas and the bacillus prodigiosus. Trans Am Surg Assoc 1894; 12:183.Google Scholar
  2. 2.
    Coley W. The therapeutic value of the mixed toxins of the streptococcus of erysipelas and the bacillus prodigiousus. Am J Med Sci 1896; 112:251–281.CrossRefGoogle Scholar
  3. 3.
    Gross L. Intradermal immunization of C3H mice against sarcoma that originated in an animal of the same line. Cancer Res 1943; 3:326–33.Google Scholar
  4. 4.
    Riker A, Cormier J, Panelli M, et al. Immune selection following antigen specific immunotherapy of melanoma. Surgery 1999; 126(2):112–20.PubMedGoogle Scholar
  5. 5.
    Dudley M, Wunderlich J, Yang J, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23(10):2346–57.PubMedCrossRefGoogle Scholar
  6. 6.
    Reynolds S, Celis E, Sette A, et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998; 161:6970–6976.PubMedGoogle Scholar
  7. 7.
    Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther 2002; 2(3):335–42.PubMedCrossRefGoogle Scholar
  8. 8.
    Dillman R, Weimann M, Nayak S, et al. Interferon-gamma or granulocyte-macrophage colony-stimulating factor adminstered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. J Immunother 2003; 26(4):367–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Mazzaferrro V, Coppa J, Carrabba M, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003; 9(9):3235–45.Google Scholar
  10. 10.
    Coca A, Dorrance G, Lebredo M. Vaccination in cancer: a report of the results of vaccination therapy as applied to seventy-nine cases of human cancer. Journal of Immunology and Experimental Therapeutics 1912; 13:543–51.Google Scholar
  11. 11.
    Berd D, Sato T, Maguire H, et al. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004; 22(3):403–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Morton D, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996; 46(4):225–44.PubMedGoogle Scholar
  13. 13.
    Ackerman A, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 20004; 5(7):678–84.CrossRefGoogle Scholar
  14. 14.
    Mitchell M. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25(6):623–35.PubMedGoogle Scholar
  15. 15.
    Marcove R, Southam C, Levin A, al e. A clinical trial of autogenous vaccine in osteogenic sarcoma in patients under the age of twenty-five. In Mathe G, Weiner R, eds. Investigation and stimulation of immunity in cancer patients. New York: Springer-Verlag, 1974.Google Scholar
  16. 16.
    Lindenmann J, Klein P. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 1967; 126:93.PubMedCrossRefGoogle Scholar
  17. 17.
    Bystryn J. Shedding and degradation of cell-surface macromolecules and tumor-associated antigens by human melanoma. In Reisfeld R, Ferrone S, eds. Melanoma antigens and antibodies. New York: Plenum Press, 1982. pp. 37–52.Google Scholar
  18. 18.
    Lore K, Betts M, Brenchley J, et al. Toll-like recpetor ligands modulate dendritic cells to augment Cytomegalovirus- and HIV-1-specific T cell responses. J Immunol 2003; 171:4320–8.PubMedGoogle Scholar
  19. 19.
    Dockrell D, Kinghorn G. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2001; 48:751–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Pulendran B, Bancheereau J, Burkeholder S, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000; 165(1):566–72.PubMedGoogle Scholar
  21. 21.
    Steinman R, Cohn Z. Identification of a novel cell type in peripheral lymphoid organs of mice: Morphology, quantitation, tissue distribution. J Exp Med 1973; 137(5):1142–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Czerniecki B, Cohen P, Faries M, et al. Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Critical Rev Immunol 2001; 21(1–3):157–78.Google Scholar
  23. 23.
    Faries M, Bedrosian I, Xu S, et al. Calcium signaling inhibits interleukin-12 production and activates CD83+ dendritic cells that induce Th2 cell development. Blood 2001; 98:2489–2497.PubMedCrossRefGoogle Scholar
  24. 24.
    Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003; 21(20):3826–3835.PubMedCrossRefGoogle Scholar
  25. 25.
    Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4(3):269–70.CrossRefGoogle Scholar
  26. 26.
    Dranoff G, Mulligan R. Gene transfer as cancer therapy. Adv Immunol 1995; 58(417–54).PubMedGoogle Scholar
  27. 27.
    Mascarenhas L, Stripecke R, Case S, et al. Gene delivery to human B-precursor acute lymphoblastic leukemia cells. Blood 1998; 92(10):3537–45.PubMedGoogle Scholar
  28. 28.
    Micka B, Trojaneck B, Niemitz S, et al. Comparison of non-viral transfection methods in melanoma primary cell cultures. Cytokine 2000; 12(6):828–33.PubMedCrossRefGoogle Scholar
  29. 29.
    Lundqvist A, Noffz G, Pavlenko M, et al. Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection. J Immunother 2003; 25(6):445–54.CrossRefGoogle Scholar
  30. 30.
    Karre K, Ljunggren H, Piontek G, Kiessling R. Selective rejection of h-2-deficient lymphoma variants suggests alternative defense strategy. Nature 1986; 391(6055):675–8.CrossRefGoogle Scholar
  31. 31.
    Huang A, Bruce A, Pardoll D, Levitsky H. Does B7–1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996; 183(3):769–76.PubMedCrossRefGoogle Scholar
  32. 32.
    Horig H, Lee D, Conkright W, et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000; 49(9):504–14.PubMedCrossRefGoogle Scholar
  33. 33.
    vonMehren M, Arlen P, Tsang K, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adneocarcinomas. Clin Cancer Res 2000; 6(6):2219–28.Google Scholar
  34. 34.
    Belli F, Arienti F, Sule-Suso J, et al. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol Immunother 1997; 44(4):197–203.PubMedCrossRefGoogle Scholar
  35. 35.
    Osanto S, Brouwenstyn N, Vaessen N, et al. Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Hum Gene Ther 1993; 4(3):323–30.PubMedGoogle Scholar
  36. 36.
    Schreiber S, Kampgen E, wagner E, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin-2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther 1999; 10(6):983–93.PubMedCrossRefGoogle Scholar
  37. 37.
    Arienti F, Belli F, Napolitano F, et al. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 2000; 10(18):2907–16.CrossRefGoogle Scholar
  38. 38.
    Suminami Y, Elder E, Lotze M, Whiteside T. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother Emphasis Tumor Immunol 1995; 17(4):238–48.PubMedGoogle Scholar
  39. 39.
    Maio M, Fonsatti E, Lamaj E, et al. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 2002; 51(1):9–14.PubMedCrossRefGoogle Scholar
  40. 40.
    Mackiewicz A, Gorny A, Laciak M, et al. Gene therapy of human melanoma. Immunization of patients with autologous tumor cells secreting interleukin-6 and soluable interleukin-6 receptor. Hum Gene Ther 1995; 6:805–11.PubMedCrossRefGoogle Scholar
  41. 41.
    Moller P, Sun Y, Dorbic T, et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with good clinical performance status: a phase I clinical study. Br J Cancer 1998; 77(11):1907–16.PubMedGoogle Scholar
  42. 42.
    Sun Y, Jurgovsky K, Moller P, et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 1998; 5(4):481–90.PubMedCrossRefGoogle Scholar
  43. 43.
    Asada H, Kishida T, Hirai H, et al. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther 2002; 5(5):609–16.PubMedCrossRefGoogle Scholar
  44. 44.
    Abdel-Wahab Z, Weltz C, Hester D, et al. A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melnaoma cells: monitoring the humoral immune response. Cancer 1997; 80(3):401–12.PubMedCrossRefGoogle Scholar
  45. 45.
    Ellem K, O’Rourke M, Johnson G, et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997; 44(1):10–20.PubMedCrossRefGoogle Scholar
  46. 46.
    Soiffer R, Hodi F, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21(17):3343–50.PubMedCrossRefGoogle Scholar
  47. 47.
    Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003; 21(4):624–30.PubMedCrossRefGoogle Scholar
  48. 48.
    Palmer K, Moore J, Everard M, et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 1999; 10(8):1261–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Hirschowitz E, Foody T, Kryscio R, et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004; 22(14):2808–15.PubMedCrossRefGoogle Scholar
  50. 50.
    Ip W, Lau Y. Distinct maturation of, but not migration between, human monocyte-derived dendritic cells upon ingestion of apoptotic cells of early or late phases. J Immunol 2004; 173(1):189–96.PubMedGoogle Scholar
  51. 51.
    Kacani L, Wurm M, Schwentner I, et al. Maturation of dendritic cells in the presence of living, apoptotic and necrotic tumour cells derived from squamous cell carcinoma of head and neck. Oral Oncol 2005; 41(1):17–24.PubMedCrossRefGoogle Scholar
  52. 52.
    Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001; 93(4):539–48.PubMedCrossRefGoogle Scholar
  53. 53.
    Pietra G, Mortarini R, Parmiani G, Anichini A. Phases of apoptosis of melanoma cells, but not of normal melanocytes differently affect maturation of myeloid dendritic cells. Cancer Res 2001; 61(22):8218–26.PubMedGoogle Scholar
  54. 54.
    Hirao M, Onai N, Hiroishi K, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000; 60(8):2209–17.PubMedGoogle Scholar
  55. 55.
    Salio M, Cerundolo V, Lanzavecchia A. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells. Eur J Immunol 2000; 30(2):705–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Dalgaard J, Beckstrom K, Jahnsen F, Brinchmann J. Differential capability for phagocytosis of apoptotic and necrotic leukemia cells by human peripheral blood dendritic cells subsets. J Leukoc Biol 2005; Epub ahead of print.Google Scholar
  57. 57.
    Krause S, Neumann C, Soruri A, et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 2002; 25(5):421–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001; 50(7):337–44.PubMedCrossRefGoogle Scholar
  59. 59.
    Parkhurst M, DePan C, Riley J, et al. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 2003; 170(10):5317–25.PubMedGoogle Scholar
  60. 60.
    Kuriyama H, Shimizu K, Lee W, et al. Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol 2004; 116:169–78.Google Scholar
  61. 61.
    Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cell cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10(14):4699–708.PubMedCrossRefGoogle Scholar
  62. 62.
    Trevor K, Cover C, Ruiz Y, et al. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol Immunother 2004; 53(8):705–14.PubMedCrossRefGoogle Scholar
  63. 63.
    Shimizu K, Kuriyama H, Kjaergaard J, et al. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 2004; 27(4):265–72.PubMedCrossRefGoogle Scholar
  64. 64.
    Faries M, Morton D. Melanoma: Is immunotherapy of benefit? Advances in Surgery 2003; 37:139–169.PubMedGoogle Scholar
  65. 65.
    Morton DL, Hsueh EC, Essner R, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002; 236: 438–48.PubMedCrossRefGoogle Scholar
  66. 66.
    Vermorken J, Claessen A, vanTinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353(9150):345–50.PubMedCrossRefGoogle Scholar
  67. 67.
    Harris J, Ryan L, Hoover H, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283. J Clin Oncol 2000; 18(1):148–57.PubMedGoogle Scholar
  68. 68.
    Adler A, Gillon G, Lurie H, et al. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Response Mod 1987; 6(6):610–24.PubMedGoogle Scholar
  69. 69.
    Lytle G, McGee J, Yamanashi W, et al. Five-year survival in breast cancer treated with adjuvant immunotherapy. Am J Surg 1994; 168(1):19–21.PubMedCrossRefGoogle Scholar
  70. 70.
    Hollinshead A. Active specific immunotherapy and immunochemotherapy in the treatment of lung and colon cancer. Semin Surg Oncol 1991; 7(4):199–210.PubMedCrossRefGoogle Scholar
  71. 71.
    Hernando J, Park T, Kubler K, et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynecologic malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002; 51(1):45–52.PubMedCrossRefGoogle Scholar
  72. 72.
    Kaminski E, Goddard R, Prentice A. Dendritic cells and their potential therapeutic role in haemoatological malignancy. Leuk Lymphoma 2003; 44(10):1657–66.PubMedCrossRefGoogle Scholar
  73. 73.
    Alth G, Denck H, Fischer M, et al. Aspects of the immunologic treatment of lung cancer. Cancer Chemother Rep [3] 1973; 4(2):271–4.Google Scholar
  74. 74.
    Geiger J, Hutchinson R, Hohenkirk L, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61(23):8513–9.PubMedGoogle Scholar
  75. 75.
    Stift A, Sachet M, Yagubian R, et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 2004; 10(9):2944–53.PubMedCrossRefGoogle Scholar
  76. 76.
    Wallack M, Sivanandham M, Balch C, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187(1):69–77.PubMedCrossRefGoogle Scholar
  77. 77.
    Hersey P, Coates A, McCarthy W, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002; 20:4148–4190.CrossRefGoogle Scholar
  78. 78.
    Sondak V, Liu P, Tuthill R, et al. Adjuvant immunotherapy or resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002; 20:2058–2066.PubMedCrossRefGoogle Scholar
  79. 79.
    Vaishampayan U, Abrams J, Darrah D, et al. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 2002; 8(12):3696–701.PubMedGoogle Scholar
  80. 80.
    Sosman J, Unger J, Liu P, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen epression on outcome. J Clin Oncol 2002; 20(8):2067–2075.PubMedCrossRefGoogle Scholar
  81. 81.
    Bystryn J, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of a polyvalent, shed-antigen melanoma vaccine. Clin Cancer Res 2001; 7:1882.PubMedGoogle Scholar
  82. 82.
    Hsueh E, Essner R, Foshag L, et al. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann Surg Oncol 2002; 9(5):486–92.PubMedCrossRefGoogle Scholar
  83. 83.
    Hsueh E, Famatiga E, Gupta R, et al. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival. Ann Surg Oncol 1998; 5(7):595–602.PubMedCrossRefGoogle Scholar
  84. 84.
    Keiholz U, Weber J, Finke J, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25(2):97–138.CrossRefGoogle Scholar
  85. 85.
    Hsueh EC, Gupta RK, Qi K, et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16: 2913–20.PubMedGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Mark B. Faries
    • 1
  • Donald L. Morton
    • 1
  1. 1.From the Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories of the John WayneCancer Institute at Saint John’s Health CenterSanta Monica

Personalised recommendations